68Ga-Dota-nt-20.3 Neurotensin Receptor 1 PET Imaging As a Surrogate for Neuroendocrine Differentiation of Prostate Cancer.
Wenyu Wu,Fei Yu,Pengjun Zhang,Ting Bu,Jingjing Fu,Shuyue Ai,Qinqin You,Liang Shi,Guoqiang Shao,Feng Wang,Marina Hodolic,Hongqian Guo
DOI: https://doi.org/10.2967/jnumed.121.263132
2022-01-01
Abstract:Prostate-specific membrane antigen (PSMA)-negative neuroendocrine prostate cancer (PCa) is a subtype of PCa likely to be lethal, with limited clinical diagnostic and therapeutic options. High expression of neuro-tensin receptor subtype 1 (NTR1) is associated with neuroendocrine differentiation of PCa, which makes NTR1 a potential target for neuro-endocrine PCa. In this study, the NTR1-targeted tracer Ga-68-DOTA-NT-20.3 was synthesized, and its affinity to androgen-dependent (LNCap) and androgen-independent (PC3) xenografts was determined. Methods: Ga-68-DOTA-NT-20.3 was labeled using an automated syn-thesizer module, and its stability, labeling yield, and radiochemical purity were analyzed by radio & ndash;high-performance liquid chromatogra-phy. Receptor binding affinity was evaluated in NTR1-positive PC3 cells by a competitive binding assay. The biodistribution of Ga-68-DOTA-NT-20.3 in vivo was evaluated in PC3 and LNCap xenografts by small-animal PET imaging. NTR1 expression was identified by immu-nohistochemistry and immunofluorescence evaluation. Results: Ga-68-DOTA-NT-20.3 was synthesized successfully, with a yield of 88.07% +/- 1.26%, radiochemical purity of at least 99%, and favorable stability. The NTR1 affinity (half-maximal inhibitory concentration) for Ga-68-DOTA-NT-20.3 was 7.59 +/- 0.41 nM. Small-animal PET/CT of PC3 xenograft animals showed high-contrast images with intense tumor uptake, which revealed specific NTR1 expression. The tumors showed significant radioactivity (4.95 +/- 0.67 percentage injected dose per gram of tissue [%ID/g]) at 1 h, which fell to 1.95 +/- 0.17 %ID/g (P < 0.01, t = 8.72) after specific blockage by neurotensin. LNCap xeno-grafts had no significant accumulation (0.81 +/- 0.06 %ID/g) of 68Ga-DOTA-NT-20.3 at 1 h. In contrast, 68Ga-PSMA-11 was concentrated mainly in LNCap xenografts (8.60 +/- 2.11 %ID/g), with no significant uptake in PC3 tumors (0.53 +/- 0.05 %ID/g), consistent with the in vitro immunohistochemistry findings. Biodistribution evaluation showed rapid clearance from the blood and main organs (brain, heart, lung, liver, muscle, and bone), with significantly high tumor-to-liver (4.41 +/- 0.73) and tumor-to-muscle (12.34 +/- 1.32) ratios at 60 min after injec-tion. Conclusion: Ga-68-DOTA-NT-20.3 can be efficiently prepared with a high yield and high radiochemical purity. Its favorable biodistribution and prominent NTR1 affinity make Ga-68-DOTA-NT-20.3 a potential radiopharmaceutical for the detection of PSMA-negative PCa and identification of neuroendocrine differentiation.